NCT01199965View on ClinicalTrials.gov

Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Healthy Subjects

Interventions

DRUG

MAP0004

1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol

DRUG

IV DHE

IV DHE administered at Visit 2 or 3 as per protocol

Trial Locations (1)

CF48 4DR

Simbec Research Limited, Merthyr Tydfil

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY